Joseph S. Zakrzewski - Mar 29, 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Joseph Zakrzewski
Stock symbol
ANTX
Transactions as of
Mar 29, 2022
Transactions value $
$0
Form type
4
Date filed
3/31/2022, 08:15 PM
Previous filing
Mar 24, 2022
Next filing
May 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Conversion of derivative security +98.2K 98.2K Mar 29, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Series A Convertible Preferred Stock Conversion of derivative security $0 -98.2K -100% $0.00* 0 Mar 29, 2022 Common Stock 98.2K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.